Global Information
회사소개 | 문의 | 비교리스트

중증 근무력증 : 시장 기회 평가, 역학 예측, 시장 동향, 파이프라인 제품 분석

Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019

리서치사 GervanoRA Data Services LLP
발행일 2020년 01월 상품 코드 920043
페이지 정보 영문 151 Pages
가격
US $ 2,500 ₩ 3,021,000 PDF by E-mail (General License)


중증 근무력증 : 시장 기회 평가, 역학 예측, 시장 동향, 파이프라인 제품 분석 Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019
발행일 : 2020년 01월 페이지 정보 : 영문 151 Pages

세계의 중증 근무력증(Myasthenia Gravis)용 의약품 시장에 대해 분석했으며, 질환의 개요와 역학 동향의 전망, 미충족 요구와 시장 기회, 주요 자본 거래의 동향(M&A, 사업 협력 등) 파이프라인 제품의 분석과 임상 시험의 진행 상황, 현재·미래의 경쟁 환경, 주요 기업의 SWOT 분석, 신규 기업의 개요와 시장 기회 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 개요

  • 분석 요약
  • 중증 근무력증 시장 : 최근의 주요 동향
  • 주요 분석 결과 : 시장 촉진·억제 요인, 시장 기회

제3장 중증 근무력증 : 질환 개요

  • 질환의 정의와 증상
  • 질환의 원인과 분류
  • 진단 방법
  • 치료 알고리즘과 가이드라인
  • 역학 조사
    • 세계의 지금까지의 발병 동향
  • 역학 예측
    • 예측 방법과 전제 조건
    • 확률적·역학적 예측

제4장 중증 근무력증 시장 역학 : 경쟁 환경

  • 거래 동향
    • 기업인수합병(M&A)
    • 협업·합의
    • 라이선스 계약
    • 자본 거래
  • 특허 분석(소멸·제네릭화)
    • 파이프라인 의약품의 특허 분석

제5장 중증 근무력증 : 파이프라인 의약품 분석

  • 파이프라인 의약품 분석 : 임상 시험 단계별
    • 제III상 파이프라인 의약품
    • 제II상 파이프라인 의약품
    • 제I상의 파이프라인 의약품
    • 전임상 단계의 파이프라인 의약품
    • 초기 연구개발(R&D) 단계의 파이프라인 의약품
    • 철수·중지 파이프라인 의약품
  • 파이프라인 의약품 분석 : 지역별
    • 미충족 요구와 시장 기회
  • 파이프라인 의약품 분석 : 투여 경로별
    • 미충족 요구와 시장 기회
  • 파이프라인 의약품 분석 : 약제 클래스별
    • 미충족 요구와 시장 기회
  • 파이프라인 의약품 분석 : 작용기서별
    • 미충족 요구와 시장 기회
  • 파이프라인 의약품 분석 : 표적별
  • 파이프라인 의약품 분석 : 기업 종류별
  • 파이프라인 의약품 분석 : 대학·연구기관 - 라이선스 계약의 시장 기회

제6장 파이프라인 의약품의 임상 단계 : 요약 및 임상 시험의 마일스톤

  • 제III상 파이프라인 의약품 : 요약 및 임상 마일스톤
    • ALEXION PHARMACEUTICALS INC - SOLIRIS(ECULIZUMAB)
    • ALEXION PHARMACEUTICALS INC - ULTOMIRIS
    • ARGENX SE - EFGARTIGIMOD(ARGX-113)
    • CATALYST PHARMA - FIRDAPSE(AMIFAMPRIDINE PHOSPHATE)
    • UCB SA - ROZANOLIXIZUMAB/UCB7665
    • RA PHARMACEUTICALS INC - ZILUCOPLAN
  • 제II상 파이프라인 의약품 : 요약 및 임상 마일스톤
    • IMMUNOVANT - IMVT-1401
    • DAS THERAPEUTICS - GTB-004/DAS-MG
    • MOMENTA PHARMACEUTICALS INC - NIPOCALIMAB(M281)
    • CARTESIAN THERAPEUTICS - DESCARTES-08
    • ALEXION PHARMACEUTICALS INC - ALXN 1830
  • 제I상 파이프라인 의약품 : 요약 및 임상 마일스톤
    • ALPHA CANCER TECHNOLOGIES INC - ACT-101(AFP)
    • KASHIV BIOSCIENCES LLC/AMNEAL PHARMACEUTICALS - K127(PYRIDOSTIGMINE)

제7장 중증 근무력증의 파이프라인 의약품 : 승인 스케줄 예측

  • 분석 방법
  • 미국내/국외에서의 승인 스케줄(추정)

제8장 시장 기회의 평가 : 기업간 벤치마킹

  • 외부에 의존
  • 파이프라인 제품 포트폴리오
  • 시장 진출 전망
  • 특허 및 독점
  • 판매 동향과 제휴 활동
  • 규제상 특별 대우의 획득 상황
  • 기업의 발전

제9장 현재/미래의 경쟁 환경 평가 : 기업 개요

  • 기존 기업
    • 주요 기업의 개요와 SWOT 분석
      • ALEXION PHARMACEUTICALS INC
      • UCB SA
      • TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • NOVARTIS AG
      • CATALYST PHARMACEUTICALS INC
  • 신규 기업
    • 주요 신규 기업의 개요와 경쟁 기회의 평가
      • ARGENX SE
      • ALPHA CANCER TECHNOLOGIES INC
      • MOMENTA PHARMACEUTICALS INC
      • RA PHARMACEUTICALS INC
      • VIELA BIO, INC.
      • GT BIOPHARMA
      • IMMUNOVANT, INC
      • KASHIV BIOSCIENCES LLC
      • CARTESIAN THERAPEUTICS, INC
      • AKARI THERAPEUTICS PLC
      • CABALETTA BIO INC
      • NEUROTUNE AG
      • TOLERANZIA AB
      • AHEAD THERAPEUTICS SL

제10장 약어 리스트

KSA 20.01.15

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: SIGNS AND SYMPTOMS OF MG
  • TABLE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY (2019) AND FORECAST (2020-2025), IN MILLION
  • TABLE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY (2019) AND FORECAST (2020-2025), IN MILLION
  • TABLE 05: PHASE 3 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 06: PHASE 2 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 07: PRECLINICAL MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 08: TERMINATED DRUGS FOR MG
  • TABLE 09: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY ORAL AS ROA
  • TABLE 11: DRUG CLASSES SCENARIO IN THE MG DRUG PIPELINE
  • TABLE 12: COMMON TARGETS IN THE MG DRUG PIPELINE
  • TABLE 13: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 14: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY UNIVERSITIES
  • TABLE 15: ESTIMATED APPROVAL TIMELINE OF KEY PIPELINE DRUGS FOR MYASTHENIA GRAVIS
  • TABLE 16: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 17: MAJOR PRODUCTS OF AMGEN WITH SALES IN FIRST NINE MONTHS FOR 2018 AND 2019 RESPECTIVELY
  • TABLE 18: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO HEMATOLOGY THERAPEUTIC AREA
  • TABLE 19: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO NEUROLOGY THERAPEUTIC AREA
  • TABLE 20: RESEARCH AND DEVELOPMENT ACTIVITIES OF ALEXION
  • TABLE 21: RECENT DEVELOPMENTS OF ALEXION
  • TABLE 22: MAJOR PRODUCTS OF UCB SA
  • TABLE 23: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO IMMUNOLOGY THERAPEUTIC AREA
  • TABLE 24: RESEARCH AND DEVELOPMENT ACTIVITIES OF UCB
  • TABLE 25: RECENT DEVELOPMENTS OF UCB
  • TABLE 26: MAJOR PRODUCTS OF TAKEDA
  • TABLE 27: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO ONCOLOGY THERAPEUTIC AREA
  • TABLE 28: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO GASTROENTEROLOGY THERAPEUTIC AREA
  • TABLE 29: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO RARE DISEASE THERAPEUTIC AREA
  • TABLE 30: PRODUCTS UNDER DEVELOPMENT WITH RESPECT TO NEUROSCIENCE THERAPEUTIC AREA
  • TABLE 31: RESEARCH AND DEVELOPMENT ACTIVITIES OF TAKEDA
  • TABLE 32: RECENT DEVELOPMENTS OF TAKEDA
  • TABLE 33: NOVARTIS'S SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 34: NOVARTIS'S IN REGISTRATION MOLECULES
  • TABLE 35: NOVARTIS'S PHASE 3 MOLECULES
  • TABLE 36: NOVARTIS'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 37: NOVARTIS'S RECENT DEVELOPMENTS
  • TABLE 38: NOVARTIS'S ANTICIPATED MILESTONES
  • TABLE 39: CATALYST PRODUCT PIPELINE
  • TABLE 40: CATALYST RESEARCH AND DEVELOPMENTS
  • TABLE 41: CATALYST RECENT DEVELOPMENTS
  • TABLE 42: ARGENX PIPELINE ASSETS
  • TABLE 43: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF ARGENX SE
  • TABLE 44: ANTICIPATED NEAR FUTURE MILESTONES OF ARGENX SE
  • TABLE 45: CONFERENCES OF ARGENX SE
  • TABLE 46: ACT PIPELINE ASSETS
  • TABLE 47: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF ACT
  • TABLE 48: MOMENTA PIPELINE ASSETS
  • TABLE 49: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF MOMENTA
  • TABLE 50: ANTICIPATED NEAR FUTURE MILESTONES OF MOMENTA
  • TABLE 51: RA PHARMACEUTICALS PIPELINE ASSETS
  • TABLE 52: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF RA PHARMACEUTICALS
  • TABLE 53: PRESENTATIONS AND PUBLICATIONS OF RA PHARMACEUTICALS
  • TABLE 54: VIELA BIO PIPELINE ASSETS
  • TABLE 55: RECENT DEVELOMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF VIELA BIO
  • TABLE 56: ANTICIPATED NEAR FUTURE MILESTONES OF VIELA BIO
  • TABLE 57: GT BIOPHARMA PIPELINE ASSETS
  • TABLE 58: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF GT BIOPHARMA
  • TABLE 59: IMMUNOVANT PIPELINE ASSETS
  • TABLE 60: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF IMMUNOVANT
  • TABLE 61: ANTICIPATED NEAR FUTURE MILESTONES OF IMMUNOVANT
  • TABLE 62: PRESENTATION OF IMMUNOVANT
  • TABLE 63: KASHIV BIOSCIENCES 505(B) (2) PIPELINE ASSETS
  • TABLE 64: KASHIV BIOSCIENCES BIOSMILARS PIPELINE ASSETS
  • TABLE 65: KASHIV BIOSCIENCES PRODRUGS PIPELINE ASSETS
  • TABLE 66: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF KASHIV BIOSCIENCES
  • TABLE 67: CARTESIAN THERAPEUTICS PIPELINE ASSETS
  • TABLE 68: RECENT DEVELOMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF CARTESIAN
  • TABLE 69: AKARI PIPELINE ASSETS
  • TABLE 70: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF AKARI THERAPEUTICS
  • TABLE 71: CABALETTA PIPELINE ASSETS
  • TABLE 72: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF CABALETTA
  • TABLE 73: NEUROTUNE AG PIPELINE ASSETS
  • TABLE 74: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF NEUROTUNE AG
  • TABLE 75: TOLERANZIA AB PIPELINE ASSETS
  • TABLE 76: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF TOLERANZIA AB
  • TABLE 77: AHEAD THERAPEUTICS PIPELINE ASSETS
  • TABLE 78: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF AHEAD THERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN MYASTHENIA GRAVIS DISEASE AREA
  • FIGURE 02: MYASTHENIA GRAVIS DISEASE CLASSIFICATION
  • FIGURE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY FORECAST (2019-2025)
  • FIGURE 05: MYASTHENIA GRAVIS DEALS SCENARIO
  • FIGURE 06: MYASTHENIA GRAVIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 07: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 08: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 09: SPLIT UP BY HSD WITH RESPECT TO INJECTABLE ROUTE
  • FIGURE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 11: TOP 5 COMPANIES WITH RESEARCH AND DEVELOPMENT EXPENSES MADE BETWEEN 2014 AND 2018
  • FIGURE 12: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 13: EXPECTED U.S MARKET ENTRIES IRRESPECTIVE OF MYASTHENIA GRAVIS TREATMENTS
  • FIGURE 14: EXPECTED U.S MARKET ENTRY WITH RESPECT TO MYASTHENIA GRAVIS TREATMENT
  • FIGURE 15: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 16: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF MYASTHENIA GRAVIS TREATMENTS
  • FIGURE 17: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO MYASTHENIA GRAVIS
  • FIGURE 18: RANKING TOP 6 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 19: R&D EXPENSES AS WELL AS NET SALES FOR YEARS 2016, 2017 AND 2018 MADE BY ALEXION
  • FIGURE 20: PRODUCT SALES AND R&D EXPENSES FOR THE FIRST NINE MONTHS OF 2018 AND 2019
  • FIGURE 21: UCB'S RESEARCH AND DEVELOPMENT EXPENSES AND NET SALES FOR 2017 AND 2018
  • FIGURE 22: UCB'S SALES BREAKDOWN FOR FIRST SIX MONTHS OF 2019
  • FIGURE 23: REVENUES ATTAINED, R &D EXPENSES BY TAKEDA ENDED ON 31 MARCH 2018 & 2019
  • FIGURE 24: GEOGRAPHICAL DISTRIBUTION OF REVENUES EARNED BY TAKEDA IN 2019
  • FIGURE 25: NOVARTIS'S REVENUES EARNED IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 26: NOVARTIS'S BREAKDOWN OF REVENUES EARNED IN THE YEAR END OF 2018
  • FIGURE 27: RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2018, 2017 (MILLION $)
  • FIGURE 28: RESEARCH AND DEVELOPMENT EXPENSE OF ARGENX SE IN THOUSANDS (2017 AND 2018)
  • FIGURE 29: R&D EXPENSE OF MOMENTA PHARMACEUTICALS IN THOUSANDS (2016, 2017 AND 2018)
  • FIGURE 30: RESEARCH AND DEVELOPMENT EXPENSE OF RA PHARMACEUTICALS IN THOUSANDS (2017 AND 2018)
  • FIGURE 31: RESEARCH AND DEVELOPMENT EXPENSE OF AKARI THERAPEUTICS IN US DOLLARS (2017 AND 2018)
  • FIGURE 32: R&D EXPENSES OF CABALETTA FOR THREE & NINE MONTHS IN THOUSANDS (ENDED SEPTEMBER 30, 2019)

GervanoRA's pipeline analysis and opportunity assessment report "Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019" analyzed and assessed Myasthenia Gravis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Myasthenia Gravis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, Pipeline Analytics by Target and Pipeline Analytics by Companies.

Our comprehensive analysis on the Myasthenia Gravis drug pipeline identified a total of 29 drug candidates undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, seven molecules are in the Phase 3 stage of development, seven molecules are in Phase 2, two molecules are in Phase 1 and a total of 13 molecules are in non clinical stage of development. We have also identified six drug molecules which have been discontinued or terminated due to various reasons from further development for Myasthenia Gravis.

The report has covered more than 25 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 14 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
  • Current and Future Competitive Landscape
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2 KEY EVENTS IN THE MYASTHENIA GRAVIS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. MYASTHENIA GRAVIS DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS OF MYASTHENIA GRAVIS DISEASE COMPETITIVE SPACE

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 MERGERS AND ACQUISITIONS
    • 4.1.2 COLLABORATION AGREEMENTS
    • 4.1.3 LICENSING AGREEMENTS
    • 4.1.4 FINANCING DEALS
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE DRUGS ANALYTICS OF MYASTHENIA GRAVIS DISEASE

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 PIPELINE DRUGS
    • 5.1.2. PHASE 2 PIPELINE DRUGS
    • 5.1.3. PHASE 1 PIPELINE DRUGS
    • 5.1.4. PRECLINICAL PIPELINE DRUGS
    • 5.1.5. EARLY R&D PIPELINE DRUGS
    • 5.1.6. WITHDRAWN AND TERMINATED PIPELINE DRUGS
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE DRUGS ANALYTICS BY TARGET
  • 5.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • 5.8. PIPELINE DRUGS ANALYTICS BY UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES

6. CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • ALEXION PHARMACEUTICALS INC - SOLIRIS (ECULIZUMAB)
  • ALEXION PHARMACEUTICALS INC - ULTOMIRIS
  • ARGENX SE - EFGARTIGIMOD (ARGX-113)
  • CATALYST PHARMA - FIRDAPSE (AMIFAMPRIDINE PHOSPHATE)
  • UCB SA - ROZANOLIXIZUMAB/UCB7665
  • RA PHARMACEUTICALS INC - ZILUCOPLAN
  • 6.2. PHASE 2 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • IMMUNOVANT - IMVT-1401
  • DAS THERAPEUTICS - GTB-004/DAS-MG
  • MOMENTA PHARMACEUTICALS INC - NIPOCALIMAB (M281)
  • CARTESIAN THERAPEUTICS - DESCARTES-08
  • ALEXION PHARMACEUTICALS INC - ALXN 1830
  • 6.3. PHASE 1 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • ALPHA CANCER TECHNOLOGIES INC - ACT-101 (AFP)
  • KASHIV BIOSCIENCES LLC/AMNEAL PHARMACEUTICALS - K127 (PYRIDOSTIGMINE)

7. ESTIMATED APPROVAL TIMELINES OF MYASTHENIA GRAVIS PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

9. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES

  • 9.1. ESTABLISHED COMPANIES
    • 9.1.1. KEY COMPANY PROFILES AND SWOT ANALYSIS
      • 9.1.1.1. ALEXION PHARMACEUTICALS INC
      • 9.1.1.2. UCB SA
      • 9.1.1.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 9.1.1.4. NOVARTIS AG
      • 9.1.1.5. CATALYST PHARMACEUTICALS INC
  • 9.2. EMERGING COMPANIES
    • 9.2.1. KEY EMERGING COMPANY PROFILES WITH COMPETITIVE OPPORTUNITY ASSESSMENTS
      • 9.2.1.1 ARGENX SE
      • 9.2.1.2. ALPHA CANCER TECHNOLOGIES INC
      • 9.2.1.3. MOMENTA PHARMACEUTICALS INC
      • 9.2.1.4. RA PHARMACEUTICALS INC
      • 9.2.1.5. VIELA BIO, INC.
      • 9.2.1.6. GT BIOPHARMA
      • 9.2.1.7. IMMUNOVANT, INC
      • 9.2.1.8. KASHIV BIOSCIENCES LLC
      • 9.2.1.9. CARTESIAN THERAPEUTICS, INC
      • 9.2.1.10. AKARI THERAPEUTICS PLC
      • 9.2.1.11. CABALETTA BIO INC
      • 9.2.1.12. NEUROTUNE AG
      • 9.2.1.13. TOLERANZIA AB
      • 9.2.1.14. AHEAD THERAPEUTICS S.L

10. ABBREVIATIONS

Back to Top
전화 문의
F A Q